Optimus Receives Tentative Approval from U.S. FDA for Brexpiprazole Tablets

Hyderabad (Telangana) [India], October 09: Optimus Pharma Private Limited today announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for the generic equivalent of Rexulti® Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, of Otsuka Pharmaceutical Co., Ltd. Optimus Pharma’s approval for its Abbreviated New Drug Application (ANDA) BREXPIPRAZOLE Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, was received on October 8th, 2021. BREXPIPRAZOLE will be manufactured at Optimus Pharma’s Pashmylaram USFDA accredited facility in India.

BREXPIPRAZOLE Tablets (RLD: Rexulti® Tablets) had estimated annual sales of USD 1258 million in the U.S. (IQVIA MAT July 2021).

BREXPIPRAZOLE has a favourable antipsychotic profile in terms of improvement of cognitive performance and sleep patterns, as well as effects on affective states and potential to treat core symptoms in schizophrenia and major depressive disorder, including cognitive deficits with a low risk of adverse effects (extrapyramidal symptoms, metabolic complications, weight gain, akathisia potential) that are commonly encountered with other typical and second-generation antipsychotic drugs. From the studies done so far, it can be concluded that BREXPIPRAZOLE can be effective monotherapy for schizophrenia and as an adjunct to other antidepressant medications in major depressive disorder.

About Optimus Pharma

Optimus was established in the year 2004 as a custom synthesis laboratory by a team of techno-commercial experts. It is one of the fastest-growing Manufacturer in Active Pharmaceutical Ingredients (APIs) and Finished dosages. Over the last decade, we have been certified and audited by reputed Global Regulatory Agencies like USFDA, WHO, COFEPRIS, EMA, KFDA and AFM from PMDA Japan. Optimus Pharma is a vertically integrated pharmaceutical company engaged in the manufacturing of Solid Oral and semisolid formulations. We have successfully integrated our API and Formulation R&D teams, with the IP and Regulatory Affairs team in order to ensure a dynamic product portfolio. We help our customers serve global markets with technology based, innovative, cost effective & consumer friendly products of the highest quality.

Leave a Reply

Your email address will not be published.

Business

Pioneers in Sustainability: Aluminium Paving the Way for the Metal Industry

The article is provided by Mr. Deepak Mathur, Sr. Vice President, Global Marketing and Sales at Jindal Aluminium Limited November 26: The world is quickly moving towards reducing its carbon footprint by cutting emissions and saving the environment from further degradation. In this path that leads us to a sustainable future, there is one metal […]

Read More
Business

Ameet Parekh Supporting Entrepreneurs to Get through the New Normal

November 26: Ameet Parekh, being an entrepreneur himself, knows the huge task of trying to build a business in this new normal. He continues to help entrepreneurs from all backgrounds in getting back on their feet. Taking his mission further, he has launched yet another edition of ‘Business Freedom Challenge’, an extremely powerful online webinar […]

Read More
Business

Interior Design Market Expected to Grow Multifold in Near Future

November 25: Urbanization is on rapid bloom. Whether it is a trend or mere a need, the population has been moving towards urban cities with new hope and better life. As per an article published by the UN, it is estimated that about 68% of the world’s population would live in urban areas by 2050. […]

Read More